Inovio Pharmaceuticals, Inc.
INO
$1.64
-$0.05-2.68%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -70.02% | -10.42% | -69.20% | -60.52% | -73.82% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -70.02% | -10.42% | -69.20% | -60.52% | -73.82% |
| Cost of Revenue | -28.32% | -28.95% | -18.93% | -6.14% | -10.71% |
| Gross Profit | 28.20% | 29.00% | 18.54% | 5.61% | 10.08% |
| SG&A Expenses | -11.66% | -5.35% | -6.74% | -10.40% | -11.46% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -22.85% | -21.78% | -15.02% | -7.60% | -10.96% |
| Operating Income | 22.76% | 21.80% | 14.73% | 7.27% | 10.54% |
| Income Before Tax | 20.80% | 4.24% | 27.85% | 22.78% | 20.62% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 20.80% | 4.24% | 27.85% | 22.78% | 20.62% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 20.80% | 4.24% | 27.85% | 22.78% | 20.62% |
| EBIT | 22.76% | 21.80% | 14.73% | 7.27% | 10.54% |
| EBITDA | 22.81% | 21.80% | 14.51% | 6.80% | 9.95% |
| EPS Basic | 52.23% | 41.30% | 48.01% | 41.56% | 34.04% |
| Normalized Basic EPS | 52.16% | 39.49% | 39.98% | 31.81% | 24.42% |
| EPS Diluted | 52.23% | 41.30% | 48.01% | 41.56% | 34.07% |
| Normalized Diluted EPS | 52.16% | 39.49% | 39.98% | 31.81% | 24.42% |
| Average Basic Shares Outstanding | 76.43% | 57.46% | 41.80% | 37.05% | 22.48% |
| Average Diluted Shares Outstanding | 76.43% | 57.46% | 41.80% | 37.05% | 22.48% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |